SI3668859T1 - Trdne oblike zaviralca kapside HIV-a - Google Patents

Trdne oblike zaviralca kapside HIV-a

Info

Publication number
SI3668859T1
SI3668859T1 SI201830688T SI201830688T SI3668859T1 SI 3668859 T1 SI3668859 T1 SI 3668859T1 SI 201830688 T SI201830688 T SI 201830688T SI 201830688 T SI201830688 T SI 201830688T SI 3668859 T1 SI3668859 T1 SI 3668859T1
Authority
SI
Slovenia
Prior art keywords
solid forms
hiv capsid
capsid inhibitor
inhibitor
hiv
Prior art date
Application number
SI201830688T
Other languages
English (en)
Inventor
Bing Shi
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI3668859T1 publication Critical patent/SI3668859T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201830688T 2017-08-17 2018-08-16 Trdne oblike zaviralca kapside HIV-a SI3668859T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546968P 2017-08-17 2017-08-17
EP18766406.5A EP3668859B1 (en) 2017-08-17 2018-08-16 Solid forms of an hiv capsid inhibitor
PCT/US2018/000172 WO2019035904A1 (en) 2017-08-17 2018-08-16 SOLID FORMS OF HIV CAPSID INHIBITOR

Publications (1)

Publication Number Publication Date
SI3668859T1 true SI3668859T1 (sl) 2022-07-29

Family

ID=63528873

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830688T SI3668859T1 (sl) 2017-08-17 2018-08-16 Trdne oblike zaviralca kapside HIV-a

Country Status (14)

Country Link
US (2) US11267799B2 (sl)
EP (2) EP4092020A1 (sl)
JP (2) JP7136886B2 (sl)
KR (2) KR102399483B1 (sl)
CN (2) CN111051296A (sl)
AR (1) AR112413A1 (sl)
AU (4) AU2018317833C1 (sl)
CA (2) CA3070141C (sl)
ES (1) ES2916426T3 (sl)
PL (1) PL3668859T3 (sl)
PT (1) PT3668859T (sl)
SI (1) SI3668859T1 (sl)
TW (2) TW202024061A (sl)
WO (1) WO2019035904A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
EP4265299A3 (en) 2016-08-19 2024-01-17 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
TW202024061A (zh) * 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
JP7038843B2 (ja) 2018-02-16 2022-03-18 ギリアード サイエンシーズ， インコーポレイテッド Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
KR20230141905A (ko) 2018-07-16 2023-10-10 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
BR112021014576A2 (pt) 2019-01-25 2021-10-05 Brown University Composições e métodos para tratamento, prevenção ou reversão de inflamação e distúrbios associados à idade
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
EP4067349A4 (en) 2019-11-29 2022-12-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED PYRIDINE CYCLE DERIVATIVE, METHOD FOR PREPARATION AND PHARMACEUTICAL USE
EP4114527A1 (en) 2020-03-06 2023-01-11 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2021231447A1 (en) 2020-03-06 2022-09-22 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
CA3204255A1 (en) 2021-01-25 2022-07-28 Lianhong Xu Combination therapy for hiv with adenosine derivative and capsid inhibitors
WO2022247942A1 (zh) * 2021-05-28 2022-12-01 江苏恒瑞医药股份有限公司 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1007198A (en) 1911-05-24 1911-10-31 Richard D Hayward Egg-candler.
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
ES2291477T3 (es) 2001-06-27 2008-03-01 Smithkline Beecham Corporation Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
DE60223920T2 (de) 2001-06-27 2008-11-13 Smithkline Beecham Corp. Pyrrolidine als dipeptidyl-peptidase-inhibitoren
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
KR20060124729A (ko) 2004-02-27 2006-12-05 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의신규한 화합물
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
BRPI0620010A2 (pt) 2005-12-14 2011-11-22 Bristol-Myers Squibb Company compostos ánalogos de arilpropionamida, arilacrilamida, arilpropinamida, ou arilmetiluréia, processo para sua preparação, composição farmacêutica e uso dos mesmos
RU2008144571A (ru) 2006-04-12 2010-05-20 Мерк энд Ко., Инк. (US) Пиридиламидные антагонисты кальциевых каналов т-типа
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CA2681718A1 (en) 2007-03-23 2008-10-02 University Of Massachusetts Hiv-1 protease inhibitors
CN101801925A (zh) 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
JP5524071B2 (ja) 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
JP5285709B2 (ja) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
DK2313111T3 (da) 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US20120045761A1 (en) 2009-02-25 2012-02-23 Bigtec Private Limited Probes and primers for detection of chikungunya
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US8524702B2 (en) 2009-08-18 2013-09-03 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
BR112012003757A2 (pt) 2009-08-18 2020-08-11 Ventirx Pharmaceuticals, Inc. benzoazepinas substituídas como moduladores de receptor tipo dobre de sino
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
JP5951615B2 (ja) 2010-10-01 2016-07-13 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｌｒアゴニストの治療用途および組み合わせ治療
CA2812787A1 (en) 2010-10-01 2012-04-05 Robert Hershberg Methods for the treatment of allergic diseases
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
PL2663550T3 (pl) 2011-01-12 2017-07-31 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora toll-podobnego
MX348935B (es) 2011-01-12 2017-07-03 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
KR101991327B1 (ko) 2011-03-23 2019-06-20 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
ME03782B (me) 2011-04-08 2021-04-20 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za tretman virusnih infekcija
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
JP6050329B2 (ja) 2011-05-18 2016-12-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染およびその他の疾患を治療するためのキナゾリン誘導体
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2794613B1 (en) 2011-12-20 2017-03-29 Boehringer Ingelheim International GmbH Condensed triclyclic compounds as inhibitors of hiv replication
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
MY169159A (en) 2012-02-08 2019-02-19 Janssen R&D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
US20150104511A1 (en) 2012-03-05 2015-04-16 Cipla Limited Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9284304B2 (en) * 2012-08-10 2016-03-15 Janssen Sciences Ireland Uc Substituted pyrimidines as toll-like receptor modulators
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
ES2670513T3 (es) * 2012-10-10 2018-05-30 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades
MX361585B (es) * 2012-11-16 2018-12-11 Janssen Sciences Ireland Uc Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas.
CN111303152B (zh) 2012-12-21 2023-04-11 吉利德科学公司 多环-氨基甲酰基吡啶酮化合物及其药物用途
CN104903323A (zh) 2012-12-27 2015-09-09 日本烟草产业株式会社 取代螺吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的医药用途
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
JP5860197B1 (ja) 2013-01-09 2016-02-16 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症を処置するための治療用化合物
ES2614053T3 (es) 2013-01-09 2017-05-29 Gilead Sciences, Inc. Heteroarilos de 5 miembros y su uso como antivirales
WO2014110323A1 (en) 2013-01-11 2014-07-17 Johnson Controls Technology Company Vehicle interior component having a wireless charging indicator
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
TWI706945B (zh) * 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
CN106458940A (zh) 2013-10-24 2017-02-22 百时美施贵宝公司 人类免疫缺陷病毒复制的抑制剂
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2016033243A1 (en) * 2014-08-29 2016-03-03 Gilead Sciences, Inc. Antiretroviral agents
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
PT3286166T (pt) 2015-04-23 2020-08-18 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
UY36648A (es) 2015-04-23 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Inhibidores de la replicación del virus de inmunodeficiencia humana
SI3191470T1 (sl) 2015-07-06 2019-04-30 Gilead Sciences, Inc. Modulatorji COT in postopki njihove uporabe
EP4265299A3 (en) 2016-08-19 2024-01-17 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
JP7038843B2 (ja) 2018-02-16 2022-03-18 ギリアード サイエンシーズ， インコーポレイテッド Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
KR20230141905A (ko) 2018-07-16 2023-10-10 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv

Also Published As

Publication number Publication date
AU2021206907B2 (en) 2022-11-24
KR20200039761A (ko) 2020-04-16
US11845739B2 (en) 2023-12-19
US20190084963A1 (en) 2019-03-21
TWI687415B (zh) 2020-03-11
ES2916426T3 (es) 2022-07-01
CA3070141A1 (en) 2019-02-21
JP2020531434A (ja) 2020-11-05
TW202024061A (zh) 2020-07-01
KR102497602B1 (ko) 2023-02-08
EP3668859A1 (en) 2020-06-24
WO2019035904A1 (en) 2019-02-21
CA3176006A1 (en) 2019-02-21
CN117285514A (zh) 2023-12-26
AU2021250894B2 (en) 2023-11-16
AU2021250891A1 (en) 2021-12-02
EP3668859B1 (en) 2022-03-30
US20220251069A1 (en) 2022-08-11
AU2018317833A1 (en) 2020-02-06
JP2021191798A (ja) 2021-12-16
KR102399483B1 (ko) 2022-05-19
CN111051296A (zh) 2020-04-21
AU2021250891B2 (en) 2023-11-23
AR112413A1 (es) 2019-10-23
JP7136886B2 (ja) 2022-09-13
PT3668859T (pt) 2022-07-08
TW201920140A (zh) 2019-06-01
AU2021250894A1 (en) 2021-11-25
KR20220070051A (ko) 2022-05-27
AU2018317833B2 (en) 2021-05-06
PL3668859T3 (pl) 2022-07-18
CA3070141C (en) 2023-03-07
AU2021206907A1 (en) 2021-08-19
US11267799B2 (en) 2022-03-08
AU2018317833C1 (en) 2021-10-28
EP4092020A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
PL3668859T3 (pl) Stałe postacie inhibitora kapsydu HIV
IL268282B (en) hiv inhibitory compounds
ZA201807865B (en) Formulations of an lsd1 inhibitor
HK1246277A1 (zh) Ask1抑制劑的固體形式
PT3668860T (pt) Formas de sal de colina de um inibidor da cápside do vih
EP3541932A4 (en) CRISPR-CAS9 INHIBITORS
IL273842A (en) 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors
IL257026A (en) Solid state forms of eluxadoline
IL286218A (en) Solid state forms of ripretinib
HUE047630T2 (hu) EZH2 inhibitorok
IL274627A (en) Solid state form of valbenazine
IL265628A (en) Solid state forms of valbenazine
ZA201706282B (en) Solid forms of menaquinols
EP3193939A4 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL276107A (en) Crystalline forms of psoorstam
IL264173A (en) Solid forms of ttk inhibitor
ZA201808437B (en) Determination of feedback timing
IL254666A0 (en) Crystalline forms of Aldecalcitol
IL283421A (en) Solid state forms of reproxalap
GB201721386D0 (en) Chrondogy of time-wave
GB201706876D0 (en) Detection of HIV enzymes